Entering text into the input field will update the search result below

Alnylam Pharma reports Q4 results

  • Alnylam Pharmaceuticals (NASDAQ:ALNY) Q4 results: Revenues: $37.9M (+116.6%); Operating Loss: ($147.3M) (-27.6%); Net Loss: ($142.2M) (-26.0%); Loss Per Share: ($1.48) (-12.1%); Non-GAAP Loss Per Share: ($1.20) (-11.1%); Quick Assets: $1,704.5M (+80.8%).
  • 2018 Guidance: Cash, cash equivalents and investments: ~$1.0B; Non-GAAP R&D expenses: $400M - 440M; Non-GAAP SG&A expenses: $280M - 320M.

Recommended For You

More Trending News

About ALNY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ALNY--
Alnylam Pharmaceuticals, Inc.